CASODEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Casodex, and when can generic versions of Casodex launch?
Casodex is a drug marketed by Ani Pharms and is included in one NDA.
The generic ingredient in CASODEX is bicalutamide. There are twenty-nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the bicalutamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Casodex
A generic version of CASODEX was approved as bicalutamide by ACCORD HLTHCARE on July 6th, 2009.
Summary for CASODEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 144 |
| Clinical Trials: | 101 |
| Patent Applications: | 4,482 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CASODEX |
| What excipients (inactive ingredients) are in CASODEX? | CASODEX excipients list |
| DailyMed Link: | CASODEX at DailyMed |
Recent Clinical Trials for CASODEX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Radboud University Medical Center | Phase 2 |
| Luye Pharma Group Ltd. | Phase 1 |
| Prospect Creek Foundation | Phase 1 |
Pharmacology for CASODEX
| Drug Class | Androgen Receptor Inhibitor |
| Mechanism of Action | Androgen Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for CASODEX
US Patents and Regulatory Information for CASODEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CASODEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CASODEX
See the table below for patents covering CASODEX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 8607915 | ⤷ Try a Trial | |
| Japan | H059128 | NEW THERAPEUTIC DRUG USING LH-RH OR AGONIST | ⤷ Try a Trial |
| Australia | 572938 | ⤷ Try a Trial | |
| Germany | 3372965 | ⤷ Try a Trial | |
| South Africa | 8005791 | ⤷ Try a Trial | |
| Spain | 8601106 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CASODEX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0100172 | SPC/GB95/015 | United Kingdom | ⤷ Try a Trial | |
| 0100172 | 97C0010 | Belgium | ⤷ Try a Trial | PRODUCT NAME: BICALUTAMIDUM; NAT. REGISTRATION NO/DATE: 624 S 291 F 3 19961014; FIRST REGISTRATION: GB 12619/0102 19950223 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
